03/10/2021

G1 Therapeutics announces launch of new drug COSELA (trilaciclib)

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib). Cosela is the only FDA-approved multilineage myeloprotection therapy to decrease the incidence of chemotherapy induced myelosuppression. 

For more information please see the press release here and visit www.COSELA.com.